`“08390 FIII'IIIS:
`Parenteral Medications
`V0|lll|lfl1
`Second Edition, Revised and Expanded
`
`Edited by
`
`Kenneth E. Avis
`
`The University of Tennessee
`
`Memphis, Tennessee
`
`Herbert A. liehermnn
`
`H.H. Lieberman Associates, inc.
`
`Consultant Services
`
`Livingston, New Jersey
`
`leon lathmun
`
`Lachmen Consuitant Services
`
`Westbury, New York
`
`Marcel Dekker, Inc.
`
`New York 0 Basel - Hong Kong
`
`MAIA Exhibit 1028
`
`MAIA V. BRACCO
`
`IPR PETITION
`
`
`
`
`MAIA Exhibit 1028
`MAIA V. BRACCO
`IPR PETITION
`
`
`
`
`
`Library of Congress Cataloging A in A Publication Data
`
`Pharmaceutical dosage forms, parenteral medications I edited by
`Kenneth E. Avis, Herbert A. Lieberman, and Leon Lachman. -- 2nd ed. ,
`rev. and expanded.
`p.
`cm.
`
`Includes bibliographical references and index.
`ISBN {1-8247-8576-2 (v. 1 : alk. paper)
`1. Parenteral solutions.
`2. Pharmaceutical technology.
`Kenneth E.
`II. Lieberman, Herbert A.
`III. Lachman, Leon.
`
`I. Avis,
`
`[DNLNL- 1. Infusions, Parenteral.
`WB 354 P536]
`R8201.P3?P48 1992
`615'. 19"ch0
`DNLMJ'DLC
`
`for Library of Congress
`
`2. TechnOIOg-y, Pharmaceutical.
`
`91 -38063
`CIP
`
`This book is printed on acid-free paper.
`
`Copyright © 1992 by MARCEL DEKKER, INC. All Rights Reserved
`
`Neither this book nor any pan may be reproduced or transmitted in any form
`or by any means, electronic or mechanical, including photocopying, micro-
`filming, and recording, or by any infermation storage and retrieval system.
`wilhout permission in writing from the publisher.
`
`MARCEL DEKKER, iNC.
`2T0 Madison Avenue, New York, New York 10016
`
`Current printing (last digit):
`10 9 B 7 6 5 4 3 2 l
`
`PRINTED [N THE UNITED STATES OF AMERICA
`
`
`
`
`
`
`This material may be protected by Copyright law (Title 17 US. Code)
`
` ÿ
`ÿÿ
`ÿ
`ÿÿÿÿ
`
`7 P
`
`arenteral Products of Peptides
`and Proteins
`
`Yu—Chang John Wang
`
`California Biotechnology, Inc.. Mountain View. California
`
`I.
`
`INTRODUCTION
`
`Scientific advances in molecular and cell biology have resulted in the develop-
`ment of two new biotechnologies. The first utilizes recombinant DNA to pro-
`duce protein products. Given the amino acid sequence of a protein , the gene
`responsible for producing such protein can be isolated, modified, and recom—
`bined with a plasmid DNA (Fig. 1) . The modified plasmid can then be im—
`planted into a host cell. The recombinant DNA will be replicated and tran-
`scribed by the host cell to produce the specific protein in large quantities.
`Escherichia coli have been modified to produce growth hormone and grewth
`factors, yeast to produce hepatitis B vaccine, and mammalian ceils to produce
`erythropoietinl The advantages of such production are practically unlimited
`supplies of protein of high purity, and consistent quality in lot-to-lot produc-
`tion.
`
`The second technology involves fusion of antibody~producing B-lympho—
`cytes and myeloma (tumor) cells to form hybridomas (Fig. 2). Hybridomas
`grown in vivo in ascitic fluid or in vitro in tissue culture produce a single
`species of antibody, known as monocional antibody, which recognizes a spe
`eii‘ic antigen.
`In contrast, conventional production methods in laboratory
`animals produce polyclonal antibodies that are comprised of a wide variety of
`antibodies with different affinity and antigenic specificities. Monoclonal anti—
`bodies, because of their unique properties of homogeneity, specificity, and
`affinity, can be used to:
`(1) isolate and purify proteins, e.g. , Monoclat Fac-
`tor VIII:C is produced in this fashion; (2) neutralize a- specific group of cells,
`e.g., Orthoclone (JET—3 neutralizes T-cells; (3) target‘specific cells or organs.
`e.g. , antibodies to tumor antigens allow for tumor imaging or therapy by link-
`ing imaging radioactive isotopes or cytotoxic drugs to the antibodies.
`
`283
`
`
`
`
`
`
`284
`
`Wang
`
`com
`
` Restriction
`
`Plasmid DNA
`
`Host cell
`
`Figure 1 Recombinant DNA for protein production. The technique of recom-
`bining genes from one species with those of another. Plasmid is an extrachro-
`mosomal. independently replicating small circular DNA molecule.
`(1) Restric—
`tion enzymes cut DNA at specific places. The donor DNA. represented by a
`heavy band, contains the information to produce the protein of interest.
`(2)
`Lig'ase fuses donor DNA with plasmid together.
`(3) Calcium is used to open
`cell wall or cell membrane to allow recombinant DNA to enter the host cell (bac—
`terium, yeast or mammalian cell).
`(4) Replication of the host cells and recom-
`binant DNA increase its number. Expression of the DNA produces desired
`protein.
`
`New products approved by the FDA between 1982 and 1989 derived from
`these two new biotechnologies are listed in Table 1.
`Although these tWo new biotechnologies have greatly expanded the capa-
`bility for producing large amounts of high quality proteins. not all new pro-
`tein products are produced in this way. Small proteins and peptides, such
`as calcitonin, may be produced by chemical synthesis. Human serum albumin
`is sourced from human blood, urokinase from urine, and streptokinase from
`fungi. Most of these proteins and peptides are formulated as injectable prod-
`ucts, although there are some exceptions. Cyclosporin is given per- os. Oxy-
`tocin and desmopresin are available as nasal preparations. A topical ointment,
`Elase. contains two lytic enzymes, fibrinolysin and desoxyribonuclease. in
`lyophflized form. Wound-healing growth factors are being developed for use
`as topicals.
`
`Among the parenteral formulations, most of them are in aqueous solution
`or in freeze-dried form for reconstitution. However, one of the potent luteiniz-
`ing hormone release hormone (LHRH) analogues, leuprolide. and havine somato-
`trepin have been developed as erodable microspheres for depot injection.
`
`ll. CHARACTERISTICS OF PROTEINS AND PEPTIDES
`
`A . Protein Structures
`
`Proteins and peptides are made of amino acids linked by peptide bonds. The
`sequence of these amino acids defines the protein's structure. The sequence
`of amino acids in human insulin is illustrated in Figure 3. A protein ma}r also
`show a secondary structure, which is formed by either intrachain or inter-
`chain hydrogen bonds. These bonds may result in either an c-helix or fi-sheet
`
`284
`
`284
`
`
`
`
`
`
`Parenteral Products of Peptides and Proteins
`
`285
`
`Antigen
`
`Mile fluad
`
`@
`
`Fm
`
`ems
`W
`
`<9
`
`v
`
`° “
`B-lymphocytaa "'
`
`e)
`
`Myolorna O
`“"3
`
`@ —‘=é%.
`t @ _.. 34’
`5......
`/" ‘3)
`g
`Hyhrldome
`
`“if‘lf‘ll'
`
`.
`
`YT‘i‘
`Desired
`
`antibody
`
`Fa rrnanter
`
`(1) A mouse or rat is immunized
`Figure 2 Monoclonal antibody production.
`with a specific antigen. The spleen is removed and antibody-producing cells
`(Ii-lymphocytes) are isolated.
`(2) Transformed myeloma cells from another
`animal are isolated.
`(3) B-lymphocytes are fused with myeloma cells deficient
`in a particular enzyme. to form hybridoma cells.
`(-1) Only the fusion product.
`hybridoma cells. can grow indefinitely in culture. The unfused myeIOma cells
`and lymphocytes die. The hybridoma cells are cloned and ones expressing
`the desired antibody are selected to culture in large amounts. The antibody
`can be produced by these hybridoma cells in either ascltic fluid or fermenta-
`tion tanks. The ascitic fluid or culture media is then processed to yield puri-
`fied monoclonal antibodies.
`
`structure. Figure 4 shows a peptide chain of a protein coiled to form an a-
`helix.
`
`The tertiary structure or conformation of a protein refers to the spatial.
`three-dimensional structure of the polypeptide chain. Given the primary and
`secondary structure, there are four kinds of interactions cooperating which
`may contribute to the tertiary structure of a protein. They are:
`(1) hydro-
`gen bonds betwoen residues in adjacent loops of the chain, (2) ionic interac—
`tions (salt bridges) between oppositely charged residues, (3) hydrophobic
`interactions between the aliphatic or aromatic residues, or {4) disulfide links
`ages (Fig. 5). Protein. in its native state. exists as a tight. cempact folded
`structure. The folded structure of insulin is shown in Figure 6. When the
`tertiary or secondary structure is destroyed, the protein unfolds and is in
`its denatured state.
`
`If dimers. trimers. or other oligomers are formed, the arrangement of
`these subunits is a quaternary structure. The best-known example of an
`oligomerie protein is hemoglobin that contains four chains and no disulfide
`linkages. The quaternary structure is essential to its oxygen- carrying activ-
`ity.
`Insulin also forms dimers and, in the presence of zinc. hexamers. The
`role of the zinc insulin hexamers is to provide a storage form that is thermo-
`dynamically stable and more resistant to enzymatic degradation than the un-
`associatad monomer.
`
`285
`
`285
`
`
`
`
`
`
`236
`
`Wang
`
`Table 1 Biotech Products Approved in the United States Between 1982
`and 1989
`
`Drug
`
`Insulin
`
`Company
`
`Date approved
`
`Indication
`
`Lilly
`
`October 1982
`
`Diabetes
`
`Human growth
`hormonea (hGH)
`
`Interferon
`Azb (IFN)
`
`Genentech
`Lilly
`
`Schering
`Roche
`
`Muromonab-CDI’.
`
`Ortho
`
`October 1985
`March 1987
`
`June 1986
`June 1936
`
`June 1985
`
`Hepatitis B
`vaccine
`
`Tissue plasminogen
`activator (t-PA)
`
`Merck
`
`Jul};r 1936
`
`Genentech
`
`October 1987
`
`Dwarfism
`
`Hairy cell
`leukemia
`
`Reverse kidney
`rejection
`
`Vaccine against
`hepatitis B
`
`Thrombolytic
`agent
`
`Erythropoietin (EPO)
`
`Amgen
`
`June 1989
`
`Anemia
`
`Hepatitis B vaccine
`
`SmithKline
`Biologics
`
`August 1939
`
`Vaccine against
`hepatitis B
`
`aGrcu-wth hormone from Genentech differs from Lilly's product by a single
`methionine at the N-terminus.
`
`blnterferons from Schering and Roche differ by one amino acid.
`
`In some proteins, there are carbohydrates attached to specific amino acid
`residues to form glycoproteins. For example, erythropoietin is a glycoprotein
`hormone with a molecular weight of 44 kilodsltons, having 49% of its weight
`accounted for by siaJic acid, an amino sugar. Carbohydrate residues stabilize
`the tertiary structure and may influence receptor binding. bioactivity, and
`pharmacokinetics of the protein in vivo.
`
`B .
`
`lsoeleetric Point
`
`In the scores of a potentiometric titration of a protein there is a pH at which
`the mean charge on the protein is zero. This pH is termed the isoelectric
`point, p1. Table 2 provides examples of pie for a number of therapeutic pro—
`teins and peptides. The pI may be approximately calculated from the amino
`acid composition data, i.e., pl =(pK1 + ng + pK3 .
`.
`. + pKnlz'n for n ioniz-
`able groups. However, because the dielectric constant in the immediate vicin-
`ity of an ionizable group depends on protein structure and. because hydrogen
`bonding ma}r alter dissociation constants (Has) , the true pl can differ signifi~
`cantly from the calculated one.
`Just like [alias of small organic compounds, the pl of a protein plays an
`important role in solubility.
`In general, near the pH of the isoelectric point.
`protein solubility is at its minimum. This trend is similar to the low solubility
`exhibited by a zwitterion compound.
`
`286
`
`286
`
`
`
`
`
`
`Parenteral Products of Peptides and Proteins
`
`287
`
`\
`
`383....3:Pa“E..5.2:ofi:ua:26.5whod;:3F...:3a:an.an»a:flunew.5.«no:3inHE:2an»Baum:
`on2onSSna
`
`9.3andQ5.?F35.<2.5£3.3095was5:55.33sz585:m0munmdemEon0584m959“.
`
`
`
`
`
`260amo$30an9:thm@3303magmaamazon“:.mwafid:wufifismfiuEnnmufimmmm:mfiwnom5mo
`
`
`
`man.can.mmwmxfizhmonu@655693he$300580mamagain93«an..mgou05.5..an5?»Emmam
`
`can539:92:3:fiance.93£30memacs—m“adiabfi..mé.3533.“Eva05:3Um>nomnoo3:9:
`
`
`
`
`123.5uflwfihwcm:5an539:visa80$.8549Ewfinfiouwnfitsuwmwhno:3.m.mnvmoduamm5
`
`
`
`9—H..Eimfi82:5:5?.3035quHo:93hwfi£33me25ntMo30532“5cum:mum.m3uno
`
`
`
`
`
`
`wfimEanMwas:.35SEER05no.“wfinowhfiwmmwsuflmndmEmbfioflmm£033wwwuoum:ofimuflmom
`
`
`
`.mmaaommofi:nsmfi-§fizn
`
`287
`
`
`mmx_SaQ3mn
`
`
`
`
`
`Eu»...:8:3=55.:3“onaa:“3“£15“.:51»u:bun—E
`
`ml!“
`
`287
`
`
`
`
`
`
`
`288
`
`Wang
`
`
`
`Figure II Peptide chain of a protein coiled to form an a-heh’x. Configuration
`of the helix is maintained by hydrogen bond: shown as vertical dotted lines.
`
`C. Degradation Through Covalent Bonds
`
`The degradation of proteins and peptides can be divided into two main cate-
`gories:
`these that involve a cavalent bond. and those involving a conforma—
`tional change. The latter process is often referred to as denaturstion.
`Numerous types of chemical reactions leading to modification of the co-
`valent structure are possible in a protein. The following describes only those
`that are likely to be seen in a protein or peptide formulation.
`
`Peptide Fragmentation
`
`The peptide bond (RNH—CO—R) is much more resistant to hydrolysis than is
`the ester linkage (RquCO-R) and peptide bonds are considered stable un-
`
`288
`
`288
`
`
`
`
`
`
`Parenteral Products of Peptides and Proteins
`
`289
`
`
`
`Figure 5 Interactions that stabilize folded conformation.
`
`less hydrolysis is assisted by a neighboring group. The formulation factor
`that most influences the hydrolytic rate is solution pH. The rate of hydrolyi
`sis is in direct proportion to the activity of hydronium, or hydroxide ions,
`when in acidic or alkaline pfls. respectively. A rate-pH profile for hydrolysis
`of tetraglycine is shown in Figure 'l'. The reaction minimum is in the region of
`pH 3 to 5 [2] . Published examples of stability studies on therapeutic peptides
`are: degradation of nafarelin [3] , thermal stability and degradation mecha-
`nism of secretin [4]. acid hydrolysis of captopril, a quasidipeptide [5] , and
`heat stability of urokinase [6] .
`Many peptides are stable enough to formulate as a readyito-use parenteral
`formulation. For instance. D-Trp-LHRH was stable at 60°C for 5 days and
`seven cycles of freezing and thawing; gramicidin. although used only for derma-
`tological indications when dissolved in glycols, can be autoclaved.
`Information
`available on package inserts also shows it is possible to have good long-term
`stability of peptides. Leuprolide injection has a shelf—life of at least 2 years
`under refrigeration and 3 months at room temperature. Lil-RH injection (Rele-
`fact) does not even require storage under refrigeration. Oxytocin injection
`was reported to be stable at room temperature for 5 years [7] . Protirelin. a
`tripeptide (PyrGiu-His-Pro). is stable for 20 hr at 30°C at both pH 3.3 and
`pH 6 [8].
`Certain amino acids form the weak link of the chain. The bond between
`
`aspartic acid and proline or tyrosine is sensitive to acid hydrolysis [9] . The
`resultant products are peptides with aspartic acid at the C-terminul. The C-
`terminai peptide bond adjacent to serine is also a reactive one due to the neigh—
`boring group effect of the alcohol on serine [10] .
`
`289
`
`289
`
`
`
`
`
`
`2'90
`
`Wang
`
`
`
`Figure 6 Folded three-dimensiOnsl structure of insulin. The A-chsin is ar-
`ranged between the two terminal arms of the B—ehsin and lies on top of the
`central orhelix (139-319). The hydrophobic regions are responsible for the
`association of monomer into dimers and hexamers.
`(Adapted from Ref. 1.)
`
`Table 2 p13 of Selected Proteins
`
`
`
` Proteins P1
`
`Pep sin
`
`Erythropoietin
`
`Serum albumin
`
`Growth hormone
`
`Insulin
`
`Interleukin- 2
`
`Calcitonin (salmon)
`
`Chymotrypsin
`
`Basic fibroblast growth factor
`
`Interferon— Y
`
`Lysozyme
`
`stsrelin
`
`1 . D
`
`3. 5- 4. {1
`
`4. 8
`
`5. [I
`
`5. 4
`
`'7. 8
`
`7. 8
`
`9. 1
`
`9. 8
`
`10. 0
`
`11. 0
`
`11. 3
`
`
`
`Protsmines 12. l}
`
`290
`
`290
`
`
`
`
`
`
`Parenteral Products of Peptides and Proteins
`
`2.91
`
`—2
`
`t:
`5 -3
`
`% E
`
`l
`l
`
`0_
`
`‘40
`
`3
`
`a
`
`a
`
`pH
`
`Figure T Rate-pH profile for the hydrolysis of tetraglycine. Peptide solu—
`tions containing phosphate buffer. 0. 03 M , and sodium chloride, 0. 1 M , were
`incubated at 60°C. Samples were analyzed by HPLC assay. At pl-Is 1 to 3,
`the slope is -1, indicating an acid catalyzed reaction.
`In the pH region 4 to
`T, the reaction is hydroxide ion catalyzed. The plateau at pH 8 is caused by
`change in ionization state. zwitter ion to negatively charged ion, which is less
`susceptible to hydroxide-ion attack [2].
`
`Decmtdatton
`
`Deamidation refers to the removal of ammonia from the amide (RCONH 2) moiety,
`whether it is at the end of a C—terminus or at asparagine (Asn) or glutamine
`(Gln) residues. Stability studies of insulin [11] , ACTH {12] , human growth
`hormone [13] . and Bis-26306 {10] . an LEI-RH analogue, have shown this route
`to be the major factor resulting in instability of these proteins and peptides
`in aqueous solution.
`In acidic media, the peptides deamidate by direct hydrolysis. Thus, an
`Asn or Gln residue yields an Asp or Glu peptide, respectively. The neighbor-
`ing amino acid does not affect the deamidation rate. Hydrolytic mechanisms
`in neutral or alkaline pits are more complex. however. Under these mndis
`tions, the side chain carbonyl group on the Asn or Gln residue attaches to
`the nitrogen atom on the peptide backbone to form a cyclic imide intermediate.
`Depending on which bond in the cyclic imide breaks (Fig. 8) , the reaction
`product can be:
`(1) the dos—amide peptide, (2) the isopeptide, or (3) D-
`isomers. The formation of isopeptide is sometimes referred to as transpeptida—
`tion because an extra methylene group is inserted to the peptide backbone.
`At neutral to alkaline pHs. the rate of deamidation is significantly affected by
`the size of the amino acid on the C-terminal side of the Asn or Gin residue.
`In general. Asn is more labile than Gin, and is most labile when adjacent to
`glycine. which is the least obstructive to the formation of a cyclic imide.
`Deamidation rate-pH profile is V-shaped [14]. usually with a minimal rate
`at a pH of about 4 to 5 (Fig. 9) .
`In a number of synthetic peptides the half-
`
`291
`
`291
`
`
`
`
`
`
`Wang
`
`O
`ll
`
`0|
`
`|
`cHrC-Oe R
`2
`I
`
`NH—CH—C~
`/ momon
`farmnafi‘ln
`
`292
`
`/
`
`was Formation
`
`2 \
`I
`ll
`H /N—CH—C~
`n'-uH-c.._c Rammxraflbn
`II
`0
`
`Figure 3 Reaction pathways in deamidation of asparagine. Deamidation of
`asparag‘ine or glutaminc goes through an intermediate. a cyclic imide. Three
`routes of degradation can take place, which leads to products of deamidation
`(removal of the amino group) , transpeptidation (insertion of an extra methy-
`lene group) . and racemization (D aspartic or glutamio acids).
`
`LogIt,[hr1 lb
`
`pH
`
`Figure 9 Deamidation rate-pH profile of an active segment of adrenocortico-
`tropic hormone, Val-Tyr-PrOLAsn—Gly—Ala, in aqueous solution at 37°C and
`ionic strength of I}. 5. The apparent rate is followed by the disappearance of
`the parent peak in HPLC.
`(From Ref. 14.)
`
`292
`
`292
`
`
`
`
`
`
`Parenteral Products of Peptides and Proteins
`
`293
`
`lives of deamidation reactions of Asns at 37°C in pH 1’. 2 phosphate buffer
`range from 2 days to nine years 115]. Not all Asns are equally labile; those
`buried within the interior portion of a protein are inaccessible to water and
`thus less reactive.
`In a large protein. secondary and tertiary structures
`play an important role in determining the Iite and the rate of deamidation.
`There are three asparagines in insulin (Fig. 3). the monodesemido-(A21}-
`insulin iI the prevailing degradant formed in acid solution.
`In neutral solu-
`tion, deamidation is slow at 5°C. However, when accelerated at higher stor-
`age temperatures, deamidation of lien at the BE position can be detected [11] .
`Figure 10 shows deamidation of insulin in neutral formulations at three differ—
`ent temperatures. With growth hormone, there are nine asparagines among
`191 amino acids, and deamidation occurs primarily at the Ash-149 position [13].
`
`Oxidation of Cysteine
`
`Under neutral or basic conditions, the free thiol (-Sl—I) group of a cysteine
`is the moat reactive moiety of all amino acid components. The disulfide
`(—S—S-) bond formed from the Oxidation of two thiol groups results in sig—
`nificant changes in conformation both intramolecularly and intermolecularly.
`Oxidation of the thiol group is promoted at both neutral and basic pH.
`The rate—pH profile for captopril, a quasi dipeptide, showed an increase in
`oxidation rate. starting at pH 5 (Fig. 11) . This reaction can be effectively
`retarded by the addition of a metal ohelating agent such as EDTA [5].
`A strategy to stabilize proteins that have reactive thiol groups is to re-
`place the cysteine with serine. Serine, a stable amino acid with a hydroxy
`(—OH) group . mimicks the size and polarityr of cysteine.
`In many cases,
`these serine mutants retain full biological activities.
`
`Oxidation of Methionine
`
`The methiol (—S—CH3) moiety on methionine is susceptible to oxidation to
`form methylsulfoxide (—SO—CH 3) derivatives. 0f the three methionines in
`human growth hormone, Met‘125 is most reactive, Met-14 is less so and Met—
`170 is not reactive at all [16] . The reactive methionine is likely to be the
`one exposed on a protein surface, and the unreactive one buried within the
`core. Air in the headspace of formulated and freeze~dried growth hormone
`can cause 40% of the growth hormone molecules to be oxidized during a 6 month
`storage period [17].
`
`Disulfide Exchange
`
`Disulfide exchange takes place when a cystine (disulfide) bond is reduced
`to two cysteines; one of them then reacts with another cysteine to form a new
`disulfide (Fig. 12) . The reaction is base (hydroxide ion) catalyzed and pro-
`moted by mercaptoethanol. which is sometimes used as an antioxidant. The
`reaction is concentration-dependent. and oligc-mers are frequently formed as
`a result of disulfide scrambling of bonds between peptide chains.
`Improper
`linkages of diIulfide bonds Were responsible for a reduction in biological ac-
`tivity of interleukin-2 (IL-2) (Fig. 12). There are three cysteine-s in IL-2
`at positions 58, 105, and 125. The native protein forms a disulfide linkage
`between the two cysteines at 53 and 105. Cleavage of this disulfide in IL-2
`and the subsequent formation of two less—active isomers with disulfide bonds
`
`293
`
`293
`
`
`
`
`
`
`294
`
`Wang
`
`25 C
`
`30
`
`
`
`n:O
`
` 6%dean-lids!ion
`
`Years
`
`Figure 10 Deamidation of insulin during storage of Actrapid MC (BF-formula-
`tion) at different temperatures. Each point represents the mean of analyses
`of 4-6 different batches. The desamido insulin content was determined by
`basic disc electrophoresis followed by densitometric scanning of the stained
`gels.
`(Ft-0m Ref. 11.)
`
`at incorrect positions are promoted by high pH and copper ions [13] . The
`number of disulfide bonds in therapeutic proteins can be shown in the follow-
`ing examples:
`IL—2: 1; salmon calcitonind; interferon—m2; human growth
`hormonezz; insulin: 3; urokinasezlz; t-plasminogen activator:17; albumin:17.
`
`50
`
`40
`
`I1
`9 so
`1
`
`.1."HI
`’5‘
`B 20
`.K
`
`[0
`
`
`
`
`
`?
`NeC-(EH-CHz-SH —- R-s-S-R
`CH3
`coo“
`
`Figure 11 Oxidation of the thiol moiety in captopril. Reaction rates at 50°C
`is followed by a peak on the HPLC ohromatogram. All solutions contain di—
`sodium edetate. Without the chelating agent, reaction rates are much faster.
`(From Ref. 5.)
`
`294
`
`294
`
`
`
`
`
`
`Parenteral Products of Peptides and Proteins
`
`295
`
`Native interleukin - 2
`
`61>”SH
`
`SS
`
`Denoturinq
`Conditions
`
`58 SS D5|25
`
`/ \HAlkalinepH
`
`105
`
`SH
`
`33 '25
`
`as
`
`:05 53 I25
`SH
`
`Less active forms
`
`Figure 12 Schematic representation of the various disulfidc-linked isomers of
`interleukimz [18] . Under denaturing conditions. i.e. , high temperature or
`alkaline pH, a free sulfhydryl group forms a disulfide bond with the sulfhy-
`dry] group from an existing disulfide. The results are proteins with incorrect
`disuli‘ide linkages and "non-native" conformation.
`
`With N-disulfide bonds, there exist (EN)! {2“ x N! possible isomers. Cau-
`tion must be exercised to preserve the correct disulfide linkage throughout
`the production process for therapeutic proteins.
`
`Rocemizotion
`
`The racemization reaction is catalyzed by both acid and base. Racemization
`of peptides and proteins results in the formation of diastereomers. As an
`example, racemization of the serine residue in a gonadotropin-releasing hor
`mone analogue was one of the main degradation reactions when treated with
`(1.1 N NaOI-I at 5°C for 43 hr [19] . Racemization under basic conditions is
`thought to proceed by abstraction of the cat-proton from an amino acid in a
`peptide to give a negatively charged planar carbanion. A proton can then be
`returned to this optically inactive intermediate. thus producing a mixture of
`D- and L-enantiomers for the individual amino acid (Fig. 13). Since a pep-
`tide is composed of multiple chiral centers, the product formed is a diastereo—
`mer. Racemization is biologically significant since a peptide comprised of D-
`amino acids is generally metabolized much slower than a naturally occurring
`peptide made of only L-amino acids. For this reason, many new synthetic
`peptides, agonists or antagonists, incorporate D-amino acids. A pH depend-
`ency on racemization was demonstrated in an aqueous degradation study of a
`decapeptide. its-26306 [10] . At neutral and alkaline pHs. racemization con-
`tributed to more degradation than deamidation (Fig. 14).
`
`295
`
`295
`
`
`
`
`
`
`296
`
`Wang
`
`CI-iR 0
`CHR 0
`H
`O
`I
`II
`II
`||
`|
`[I
`"NH-(IS—CN : ~NH—C—-C- .._—_" NNH-(IJ—CN
`H‘.
`«a
`CHR
`
`OH
`
`Figure 13 Racemization of an amino acid resulting in a mixture of enantiOmers.
`
`Mciiiard Reaction
`
`In the Maillsrd reaction, the carbonyl group (ROI-1:0) from glucose can react
`with the free amino group (e.g., R'NHZ in lysine) in a peptide to form a
`Schiff base (RCH=NR'). This reaction is acid catalyzed. During pasteurize-
`tion (60°C . 10 hr), the loss of antithrombin III biological activity seen in the
`presence of reducing sugars, especially glucose. was attributed to this reac-
`tion [20] . An alternative assessment of poor blood-glucose control in diabetic
`patients is the measurement of glycosylated hemoglobin, which is the product
`of the Maillard reaction. The hospital pharmacist should thus be concerned
`about storing protein in dextrose solution for a prolonged period of time.
`
`--——-r—
`
`Epimerizalion
`
`1’. Deomidution
`
`p’
`
`
`
`
`
`
` _ X.--l"'". Hydrolysis
`
`Figure “I Rate-pH profiles for degradation of 113-26306. N-acetylwii-(Zrnaph-
`thy1)«D-Ala- d-Chloro~D—Phe- 3- I: 3-pyridinyl) -D-Ala~ Ser-Tyr-N , N- diethyl-D-
`
`Arg-LeudN. N-diethyl-Arg-Pro-D-Alanylamide, a decapeptide [10].
`
`296
`
`296
`
`
`
`
`
`
`Parenteral Products of Peptides and Proteins
`
`29?
`
`Dimerizction and Polymerization
`
`Insulin forms a small amount (about 1%) of covalent dimer and polymer during
`2 years storage at 4°C. Production of these species increases dramatically
`with increasing temperature. The dimerization is mainly due to a reaction be-
`tween an N—terminal amino group in one insulin with a carboxamide group of
`a glutamine or an asparaglne in another inaulin molecule [11] .
`The covalent bond reactions aforementioned are examples of key reactions
`that may cause protein or peptide instability during storage. A complex pro-
`tein may undergo many reactions simultaneously.
`
`D . Denatu ration
`
`Specific conformation is required for proteins to exert physiological and phar-
`macological activities. Denaturation is a process of altering- protein conforma-
`tion. The denaturation process is illustrated in Figure 15 [21]. The folded
`structure (N) unwinds, passes through a critical activated state (A‘), to an
`incompletely disordered conformation (ID). Finally, some of the 13) forms
`uncoil to become random boils (RC). Heat, extreme pHs, organic solvents,
`high salt concentration, lyophilization, or mechanical stress can denature pro—
`teins.
`
`ID
`
`RC
`Laval
`
`Energy
`
`Reaction Coordinate
`
`Figure 15 Schematic illustration of reversible conformational transitions of
`c-lactalbumin [21]. N, Native conformation; A“, critical activated state; ID,
`
`incompletely disordered conformation; and RC, random coil (fully denatured
`state).
`
`297
`
`297
`
`
`
`
`
`
`298
`
`Wang
`
`Protein conformation refers to the specific tertiary structure. which is
`determined by the primary and secondary structures and the disulfide bonds,
`and is held together by three forces: hydrogen bonding, salt bridges, and
`hydrophobic interactions (Fig. 5).
`Hydrogen bonds are the most important in determining overall protein
`conformation, since they are the major forcas that stabilize the secondary
`cut-helices and B-sheets. as well as the overall folded structure.
`1Water, the
`ubiquitous medium for most proteins, contributes to this hydrogen bonding.
`Thus, to avoid denaturation in protein during a freeze-drying process, a
`small amount of residual moisture is critical for recovering biological activity
`of the reconstituted protein. Cosolvents such as ethanol and acetone, and
`chaotropic agents such as urea and guanidinium chloride disrupt the hydro-
`gen bonds thus readily denature proteins.
`The ionic side-chains of aspartic acid, glutamic acid. lysine, arginine,
`and histidine. normally found on the surface of the protein, contribute to
`the stability of the native conformation by forming salt bridges. The pH of
`the solvent will determine the charge of the side- chains on these amino acids
`and the extent of ionic bonding. Thus, an extreme pH shift can disrupt these
`salt bridges and lead to denaturation. Further. organic solvents weaken the
`streangth of salt bridges, thus, inappropriate exposure to organic solvent
`can also result in denaturation.
`
`Because hydrophobic side-chains. i.e. , phenyl and hydrocarbon chains,
`are usually tucked inside the protein's globular structure. significant stabil-
`izing effects result from their hydrophobic interactions. This interaction,
`too, is sensitive to the effects of solvents. Disruption of hydrophobic inter-
`actions is often considered the mechanism of denaturation by surfactants,
`heat, mechanical stress, or storage. When a protein molecule unfolds under
`thermal stress, and before it refolds to its natural conformation. hydrophobic
`interaction can result in one of two different types of unnatural conformations.
`In a concentrated protein solution, the hydrophobic groups may interact be-
`tween molecules. resulting in protein aggregation.
`In dilute solutions of pro-
`tein. however, intramolecular interactions are much more likely, and may re-
`sult in a conformation different from the native one. Such unnatural conformas
`tions may show partial or complete loss of biological activity.
`
`E . Analytical Methods
`
`For protein products a battery of tests are required to assure identity. purity,
`potency . and stability of the formulation. Due to complexity of proteins, as
`of yet no chemical or physical assay can substitute for a bioassay for assess-
`ing the potency. There are in vitro and in vivo bioassays. The in vitro bio-
`assay monitors the response of cells or excised tissue to the stimulation of
`hormones. growth factors, or antibodies. For example, the activity of IL-2
`is determined by measuring [3H]-thymidine incorporated into an IL—Z depend—
`ent murine T~cell line. The in vivo bioassay monitors the pharmacological
`responses of animals to the proteins. For example. the activities of insulin
`and glucagon are determined by measuring post-injection blood sugar in rab-
`bits and cats, respectively. Often . in vitro and in vivo bioassays are not
`sensitive enough to detect subtle changes in protein characteristics. Thus,
`consistency in product performance relies heavily on validated manufacturing
`
`298
`
`298
`
`
`
`
`
`
`Parenteral Products of Peptides and Proteins
`
`299
`
`processes as well as end product testing. When the manufacturing process
`or formulation is significantly changed, the only assured way to prove bio-
`equivalency is to conduct clinical studies in patients.
`The multiplicity of degradation routes for proteins requires combined in-
`formation from various assays to assess the stability of the product. The
`following sections describe common analytical methods employed in protein
`formulations .
`
`UV Spectrometry
`
`Any protein with at least one tryptophan residue can be detected, at about
`the 0.1 mglml level, by ultraviolet (UV) spectroscopy at 270 to 280 nm.
`Phenylalanine and tyrosine contribute about one-sixth the molar absorptivity
`to that of tryptophan.
`ICine may use UV for batching assay because of its
`precision, reproducibility, and simplicity. The absorptivity can be deter-
`mined from literature values or derived from the absorbsnce and mass ob-
`tained from amino—acid composition. For example. the generally accepted value
`for the absorbsnce at 2?5 nm of a 1 mglml solution of immune globulin is 1.5.
`The UV method can be a rapid assay for in-process quality control. Also.
`because protein aggregates scatter UV light with increased absorbsnce over
`the range 210 to 350 nm, [N spectrometry can be used to monitor protein ag—
`gregation.
`
`Proteins Assay
`
`Bradford, Lowry and bicinchoninic acid (BOA) assays are three commonly
`employed colorimetric assays for determination of protein content.
`The Bradford assay is based on a change in the absorption maximum .
`from 465 to 595 nm, of an aromatic sulfonate dye. Coomassie Brilliant Blue
`6-250, in the presence of protein.
`Biuret, with a structure of NHgCONHCONHg, and peptides. having a simi-
`lar structure. reduce copper to cuprous ion in alkaline solution. and conco—
`mittently a color complex i